ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2946

Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases

Kaleb Michaud1, Sofia Pedro2 and Patricia P. Katz3, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate risk of
mortality among SLE patients cohort in the NDB.

Methods: Systemic lupus erythematous
(SLE) and non-inflammatory rheumatic disease (NIRD) patients were studied from
1998 through 2011 in the National Data Bank for Rheumatic Diseases (NDB), a longitudinal
observational study following patients from all regions of the US through biannual
questionnaires. Patients were required to have at least 2 observations or 1
observation and died before 2012. Mortality was confirmed through National
Death Index-matched death records. We calculated standardized mortality ratios
(SRRs) of SLE vs. NIRD based on age-, race- and sex-stratified US population
data (CDC.gov). Cox regression models with time varying covariates were used to
investigate the risk of mortality among diagnoses. A second Cox regression
model was done at last observation using SLE specific variables.

Results: 2,374 SLE and 5,603 NIRD
patients were studied. The mean (median) time in the study for SLE patients was:
2.52 (1.71) years with a total of 5,981 patient-years of follow-up, and for
NIRD, 3.77 (2.12) years with a total of 21,090 patient-years of follow-up. At a
random observation, SLE patients were described as: mostly male (93.3%), with
an average of 50.4 (SD 13.5) years, white (73.0%), married (59%), mostly
high-graduated (93.9%), with worse disease activity measures compared to NIRD
(P<0.001 for the majority). At last observation, the BILD score was 3.36 (SD
2.08), PHQ8 scale 5.67 (SD 5-04) and GAD2 0.93 (SD 1.36).

The overall SRM were: 2.88 (95% CI 2.42-3.44) and 1.46 (95%
CI 1.37-1.55) for SLE and NIRD patients, respectively. After multivariate
adjustment (including demographic and disease severity outcomes), the hazard
ratio comparing diagnoses was 0.96 (95%CI 0.74 -1.24). Among SLE patients, univariate preditors of
mortality  (age, age-squared and sex
adjusted) were presented in Table. Almost all disease severity variables were
associated with an increased risk of mortality among the SLE cohort.

Conclusion: Predictors of mortality were studied among SLE
patients. Worse disease severity, more comorbidities and smoking habits were
all important factors to an increased risk of mortality, among others. When comparing
diagnoses, the risk of mortality did not seem to differ. The use of treatment
will be further investigated in future works.

Table – Age, age-squared and sex adjusted predictors of
mortality among SLE patients.

Cox regression

HR

95% CI

Age

0.90

0.84

0.97

Age- squared

1.00

1.00

1.00

Sex

2.37

1.47

3.83

White

0.61

0.40

0.94

Married

0.70

0.50

0.99

Widowed

1.96

1.14

3.37

Employed

0.38

0.23

0.63

Educational level (yrs)

0.90

0.84

0.96

Past smoker

1.49

1.03

2.16

Current smoker

1.86

1.10

3.15

BMI (Kg/m2)

1.02

1.00

1.05

HAQ disability (0-3)

2.30

1.82

2.90

VAS pain scale (0-10)

1.18

1.11

1.25

VAS Global (0-10)

1.19

1.11

1.27

VAS Fatigue scale (0-10)

1.14

1.08

1.21

PAS (0-10)

1.29

1.19

1.39

SF-36 PCS (0-100)

0.94

0.92

0.96

SF-36 MCS (0-100)

0.98

0.96

0.99

Comorbidity index (0-9)

1.26

1.15

1.37

VAS function scale (0-10)

1.17

1.12

1.22

Symptom intensity scale (0-10)

1.09

1.06

1.12

SLAQ score*

1.09

0.99

1.19

SLAQ flares*

Yes, mild flare

2.68

0.41

17.40

Yes, moderate flare

2.53

0.19

34.25

Yes, severe flare

14.11

1.59

124.92

* Model performed at last observation, not using time-varying covariates.


Disclosure: K. Michaud, None; S. Pedro, None; P. P. Katz, None.

To cite this abstract in AMA style:

Michaud K, Pedro S, Katz PP. Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/mortality-among-sle-patients-in-the-national-data-bank-for-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-among-sle-patients-in-the-national-data-bank-for-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology